Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01418495 · ClinicalTrials.gov registry record

Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
12
Enrollment target

NCT01418495: Completed study, sponsored by National Cancer Institute (NCI).

NCT01418495 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add start date to calendar (.ics) →

The verdict

NCT01418495 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
12 participants
Enrollment target

Study Summary

This research trial is studying how Ch14.18 acts in the body of younger patients with high-risk neuroblastoma. Studying samples of blood from patients with cancer receiving Ch14.18 may help doctors learn more about how this drug is used by the body to develop better ways to give the drug to potentially improve its effectiveness and lessen its side effects.

Primary Outcome

PK parameters include the peak concentration, trough concentration, AUC, clearance, volume of distribution, half-life, and mean residence time. PK parameters will be derived from the plasma concentration-time data. A one-compartment model fit to the concentration-time data will estimated the volume of distribution and the first order elimination rate constant, which will in turn be used to calculate clearance, half-life, AUC0-infinity, AUC0-last, and the mean residence time. An error function an

Interventions

  • OTHER Cytology Specimen Collection Procedure
  • OTHER Pharmacological Study

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2011-05-26
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT01418495 record still lists

NCT01418495 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.

The record links to 0 conditions, and to 2 interventions - of which Cytology Specimen Collection Procedure is the first listed.

NCT01418495 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01418495 about?

NCT01418495 is a clinical study titled "Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma". This research trial is studying how Ch14.18 acts in the body of younger patients with high-risk neuroblastoma. Studying samples of blood from patients with cancer receiving Ch14.18 may help doctors learn more about how this drug is used by the body to develop better ways to give the drug to potentia...

What is the current status of trial NCT01418495?

This trial is currently completed. The enrollment target is 12 participants. The study started on 2011-05-26.

What interventions are being tested in trial NCT01418495?

The interventions under investigation include: Cytology Specimen Collection Procedure (OTHER), Pharmacological Study (OTHER).

Who is sponsoring clinical trial NCT01418495?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01418495, the US trial registry maintained by the National Library of Medicine. NCT01418495 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.